We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -1.00 | -0.48% | 208.00 | 10,915 | 16:35:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 202.00 | 209.00 | 209.00 | 201.00 | 201.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 630.2M | USD 37.73M | USD - | - | 1.82B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:00 | UT | 3,719 | 208.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/5/2025 | 07:00 | UK RNS | Hutchmed (China) Limited HUTCHMED Highlights Data to be Presented at ASCO |
| 13/5/2025 | 11:45 | UK RNS | Hutchmed (China) Limited AGM held on May 13, 2025 – Poll Results |
| 24/4/2025 | 07:00 | UK RNS | Hutchmed (China) Limited HUTCHMED - Data to be Presented at AACR 2025 |
| 22/4/2025 | 08:32 | ALNC |  Hutchmed China completes enrolment for gastric cancer drug trial |
| 22/4/2025 | 07:00 | UK RNS | Hutchmed (China) Limited HUTCHMED Completes Enrollment of Phase II Study |
| 07/4/2025 | 09:30 | UK RNS | Hutchmed (China) Limited 2024 Annual Report and Notice of AGM |
| 31/3/2025 | 10:30 | UK RNS | Hutchmed (China) Limited Extraordinary General Meeting – Poll Results |
| 21/3/2025 | 12:23 | ALNC | IN BRIEF: Hutchmed China's Tazverik conditionally approved in China |
| 21/3/2025 | 10:00 | UK RNS | Hutchmed (China) Limited NMPA Conditional Approval for TAZVERIK® |
| 20/3/2025 | 14:31 | ALNC | IN BRIEF: Hutchmed highlights positive lung cancer test results |
Hutchmed (china) (HCM) Share Charts1 Year Hutchmed (china) Chart |
|
1 Month Hutchmed (china) Chart |
Intraday Hutchmed (china) Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 16/5/2025 | 08:57 | (Chi-Med)Hutchinson China Meditech Limited | 4,133 |
| 25/3/2022 | 17:25 | Hutchison Chi-Med (HCM) One to Watch | 3 |
| 23/7/2018 | 10:55 | Hutchison Chi-Med (HCM) One to Watch on Monday | 1 |
| 13/6/2017 | 07:54 | Hutchison China Meditech- CHARTS AND DISCUSSION | 74 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-05-23 15:35:00 | 208.00 | 3,719 | 7,735.52 | UT |
| 2025-05-23 15:29:34 | 209.00 | 12 | 25.08 | AT |
| 2025-05-23 15:14:15 | 207.59 | 1,443 | 2,995.57 | O |
| 2025-05-23 14:55:24 | 202.49 | 1 | 2.02 | O |
| 2025-05-23 14:25:01 | 203.12 | 1 | 2.03 | O |
| Top Posts |
|---|
Posted at 24/5/2025 09:20 by Hutchmed (china) Daily Update Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 209p.Hutchmed (china) currently has 871,601,095 shares in issue. The market capitalisation of Hutchmed (china) is -. This morning HCM shares opened at 201p |
Posted at 16/5/2025 01:53 by lauders The latest interview/presentatiIf it does work try accessing from here: The full slide deck is available via the link in the top right hand corner window pane shown on the page the first link takes you to. It will be available on the HCM website in due course. Hope the new ATTC venture proves successful. Looks interesting! |
Posted at 15/5/2025 21:09 by 1jat Oxman,The current weakness is largely the uncertainty surrounding potential tariffs and the executive order that Trump wants to reduce the prices of US drugs. HCM seems to be slightly worse than the market. There are some recent data points that may point to reductions in expectations for 2025/26 revenues: Takeda 12m sales (to end March) was Y48bn, this shows continued progress - HCM reported $291m for the year ending Dec 24, the Takeda value is approx $320m which will reflect some additional countries coming on stream. (Unclear whether this is ahead of expectations but Takeda shares fell on their results). The BoA presentation confirmed that AZ is waiting for Savannah results before making an NDA for savolitinib. HCM had previously held out the possibility of a conditional approval based on Savannah - so that is a delay to revenue. At the same meeting it was said that Sovlep approval is expected late this year. So there is some mildly adverse news and nothing positive to report. My view is that this may continue to drift lower, but that if Sovlep is approved and the US tariff and EO situation becomes clearer, then there is a good chance of a bounce. CKHH will also be flush with cash when its Ports deal gets through (expect this as part of the US/China resolution) and an offer to take off the market may occur. |
Posted at 01/4/2025 05:35 by mcmather "Shares of Hong Kong conglomerate CK Hutchison climbed 1% on Tuesday ahead of a deal to sell its Panama ports to a BlackRock-led group that is due to be signed by April 2"Probably 'commentators curse' * but HCM (HKEX) presently +10.48% *Or April Fools'! |
Posted at 22/3/2025 00:45 by lauders More good news from HCM and the share price not responding. Been an "opportunity cost" hold, but one day it may reward.HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma – First and only EZH2 inhibitor approved by the NMPA – – HUTCHMED’s fourth product, and its first approval in hematological malignancies – |
Posted at 19/3/2025 11:53 by 1jat Sales were slightly better than I expected, with the share of revenue from Takeda rising from 33% to 38% (maybe some pre-orders to beat Trump tariffs.The Inmagene reverse takeover of Ikena will leave HCM with a 3% stake in the enlarged entity. They will have a post tax profit of $400m in 2025 from the disposal….and yet still no reward for shareholders. |
Posted at 04/3/2025 17:12 by 1jat Dominant shareholder CKHH will be flush with cash later this year as it is negotiating the sale of its ports to Blackrock and others. The deal will generate about US$19bn for CKHH. Plenty of firepower if they want to take HCM private or support M&A. |
Posted at 21/2/2025 00:13 by mcmather 20 Feb 2025: HUTCHMED (HCM) Upgraded to Buy: Here's Why |
Posted at 12/2/2025 20:28 by mcmather Double yer money from here..."Feb. 11, 2025, 09:25 AM BofA raised the firm’s price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees “some regulatory headwinds potentially ahead,” the firm keeps a Buy rating on the shares and cites higher revenue expectations for key assets after “strong performance in 2024” for its revised price target" |
Posted at 12/12/2024 07:44 by lauders Good news again. Will it have any effect on the share price?Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMEDR |
Posted at 14/11/2022 06:58 by lauders Nearly +20% in HK now! Come on HCM share price at least match that! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
